Home > Back to Publisher > Report Information

U.S. HIV/AIDS Therapies Markets

Frost & Sullivan
January 27, 2003
SKU: MC856460

Abstract Table of Contents Related Reports

Countries covered: United States

Antiretroviral Drugs from Existing and Novel Categories Offer Major Growth Opportunities

Antiretroviral (ARV) drugs that prevent HIV replication are always recommended in combinations guided by the principles of highly active antiretroviral therapy (HAART), which seeks to reduce resistance, adverse reactions, and pill burdens, while improving efficacy. Existing categories- nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), and protease inhibitors (PIs)- remain at the core of HAART, with several ARV drugs in the pipeline. However, drugs under development in new categories such as entry inhibitors, immune-based therapies, zinc finger inhibitors, and integrase inhibitors have the potential to transform this dynamic market. Established and recent participants can look forward to exciting growth prospects in addressing the strong need for new antiretroviral drugs in existing and novel categories.

This Frost & Sullivan research is a detailed study of the HIV/AIDS therapies markets in the United States. It segments the market as follows: NRTIs, NNRTIs, PIs, and future therapies in novel categories. This report offers an in-depth product analysis of current antiretroviral drugs as well as those in the pipeline. It discusses major drivers, restraints, and challenges governing the market and offers strategic recommendations to overcome them.

Expanding and Alert HIV Population Boosts Demand for HIV/AIDS Therapies

Of the almost 900,000 HIV-infected people in the United States, nearly 25 percent remain unaware and undiagnosed. This is likely to generate greater demand for HIV/AIDS therapies, as more infected people are diagnosed and come forward to be treated. Effective ARV therapy will reduce mortality rates increasing the number of persons living with AIDS and seeking continual treatment.

Better and rapid testing leading to increased diagnosis as well as enhanced awareness have resulted in more people registering for tests and treatment. "Due to major efforts by HIV/AIDS-related help groups, the industry and the media, the reported cases of HIV/AIDS and consequently, the number of HIV positive people opting for treatment will increase," says the analyst.

Coordinated Communication Efforts of Help Groups, Federal Agencies, and Others Benefit Market Participants

The Red Ribbon Project has played an integral role in inspiring end users and increasing their faith in available HIV/AIDS therapies as well as those under clinical trials. It has supported the lobbying efforts of help groups to increase funding for AIDS-related services and research. Several associations and help groups are committed to educating its members on the prevention and treatment of the disease. "The powerful symbolism of the Red Ribbon is probably the most important driver of this market that heightens the hope for cure, and the urgency for treatment," says the analyst.

Additional Information

List Of Figures

Chapter 2

HIV/AIDS Therapies Markets: Reported Cases of AIDS by Exposure Category (Adolescents and Adults) (U.S.), 2002
HIV/AIDS Therapies Markets: Reported Cases of AIDS by Exposure Category (Children) (U.S.), 2002
HIV/AIDS Therapies Markets: Reported Cumulative Cases of AIDS by Age (U.S.), 2002
HIV/AIDS Therapies Markets: Reported Cumulative Cases of AIDS by Race/Ethnicity (U.S.), 2002
HIV/AIDS Therapies Markets: Reported Cumulative Cases of AIDS by Leading States/Territories (U.S.), 2002
HIV/AIDS Therapies Markets: Impact of Major Market Challenges (U.S.), 2003-2009
HIV/AIDS Therapies Markets: Market Drivers Ranked in Order of Impact (U.S.), 2003-2009
HIV/AIDS Therapies Markets: Market Restraints Ranked in Order of Impact (U.S.), 2003-2009
HIV/AIDS Therapies Markets: Average Annual Costs of Therapy (U.S.), 2002
HIV/AIDS Therapies Markets: Demand Analysis (U.S.), 1999-2009
HIV/AIDS Therapies Markets: Total Revenue Forecasts (U.S.), 1999-2009
HIV/AIDS Therapies Markets: Comparative Revenue Forecasts for Existing and New Products (U.S.), 2002-2009
HIV/AIDS Therapies Markets: Competitive Structure; Antiretroviral Drugs (U.S.), 2002
HIV/AIDS Therapies Markets: Product Range by Company (U.S.), 2002

Chapter 3

Nucleoside Reverse Transcriptase Inhibitors Market: Existing Brands (U.S.), 2002
Nucleoside Reverse Transcriptase Inhibitors Market: Drugs in Pipeline (U.S.), 2002
Nucleoside Reverse Transcriptase Inhibitors Market: Market Drivers Ranked in Order of Impact (U.S.), 2003-2009
Nucleoside Reverse Transcriptase Inhibitors Market: Market Restraints Ranked in Order of Impact (U.S.), 2003-2009
Nucleoside Reverse Transcriptase Inhibitors Market: Pricing (U.S.), 2002
Nucleoside Reverse Transcriptase Inhibitors Market: Standard Dosages and Annual Costs (U.S.), 2002
Nucleoside Reverse Transcriptase Inhibitors Market: Comparative Revenues and Growth Rates for Total, Existing and New Drugs (U.S.), 1999-2009
Nucleoside Reverse Transcriptase Inhibitors Market: Competitive Structure (U.S.), 2002

Chapter 4

Protease Inhibitors Market: Existing Brands (U.S.), 2002
Protease Inhibitors Market: Drugs in Pipeline (U.S.), 2002
Protease Inhibitors Market: Market Drivers Ranked in Order of Impact (U.S.), 2003-2009
Protease Inhibitors Market: Market Restraints Ranked in Order of Impact (U.S.), 2003-2009
Protease Inhibitors Market: Pricing (U.S.), 2002
Protease Inhibitors Market: Standard Dosages and Annual Costs (U.S.), 2002
Protease Inhibitors Market: Comparative Revenues and Growth Rates of Total, Existing and New Drugs (U.S.), 1999-2009
Protease Inhibitors Market: Competitive Structure (U.S.), 2002

Chapter 5

Non-Nucleoside Reverse Transcriptase Inhibitors Market: Existing Brands (U.S.), 2002
Non-Nucleoside Reverse Transcriptase Inhibitors Market: Drugs in Pipeline (U.S.), 2002
Non-Nucleoside Reverse Transcriptase Inhibitors Market: Market Drivers Ranked in Order of Impact (U.S.), 2003-2009
Non-Nucleoside Reverse Transcriptase Inhibitors Market: Market Restraints Ranked in Order of Impact (U.S.), 2003-2009
Non-Nucleoside Reverse Transcriptase Inhibitors Market: Pricing (U.S.), 2002
Non-Nucleoside Reverse Transcriptase Inhibitors Market: Standard Dosages and Annual Costs (U.S.), 2002
Non-Nucleoside Reverse Transcriptase Inhibitors Market: Comparative Revenues and Growth Rates of Total, Existing and New Drugs (U.S.), 1999-2009
Non-Nucleoside Reverse Transcriptase Inhibitors Market: Competitive Structure (U.S.), 2002

Chapter 6

Future HIV/AIDS Therapies Market: Pipeline Entry Inhibitors (U.S.), 2002
Future HIV/AIDS Therapies Market: Pipeline Immune Based Therapies (U.S.), 2002
Future HIV/AIDS Therapies Market: Miscellaneous Pipeline Drugs (U.S.), 2002
Future HIV/AIDS Therapies Market: Vaccines--Phase III (U.S.), 2002
Future HIV/AIDS Therapies Market: Vaccines--Phase II, I and Preclinical (U.S.), 2002

1 Executive Summary
A. Executive Summary
1 Executive Summary

2 Introduction
A. HIV/AIDS: Definition and Classification
1 Report Scope
2 The Human Immunodeficiency Virus
3 Acquired Immuno-Deficiency Syndrome(AIDS)
4 Etiology and Demography
5 Diagnostic Tests
6 Overview of HIV/AIDS Therapies
7 Highly Active Antiretroviral Therapy(HAART)
B. Challenges and Strategies
1 Overview of Challenges
2 Challenge 1: Higher Drug Resistance
3 Challenge 2: Inconsistent Patient Adherence
4 Challenge 3: Higher Pill Burdens
5 Challenge 4: Drug-Induced Dyslipidemia
6 Challenge 5: Patients' Lower Tolerability
7 Challenge 6: Limited Funds and High Drug Prices
C. Market Dynamics
1 Market Drivers
2 Market Restraints
3 Pricing Trends
4 Demand Analysis
5 Revenue Forecasts
6 Market Engineering Analysis
D. Competitive Analysis
1 Competitive Structure
2 Market Share Analysis
E. Market Engineering Awards
1 Marketing Strategy Leadership Award
2 Product Innovation Award
3 Business Development Strategy Award

3 Nucleoside Reverse Transcriptase Inhibitors Market
A. Market Overview
1 Introduction
2 Product Analysis - Existing NRTIs
3 Product Analysis - Pipeline NRTIs
4 Market Drivers
5 Market Restraints
B. Market Dynamics
1 Pricing Analysis
2 Revenue Forecasts
3 Market Engineering Analysis
C. Competitive Analysis
1 Competitive Structure
2 Market Share Analysis

4 Protease Inhibitors Market
A. Market Overview
1 Introduction
2 Product Analysis - Existing Protease Inhibitors
3 Product Analysis - Pipeline Protease Inhibitors
4 Market Drivers
5 Market Restraints
B. Market Dynamics
1 Pricing Analysis
2 Revenue Forecasts
3 Market Engineering Analysis
C. Competitive Analysis
1 Competitive Structure
2 Market Share Analysis

5 Non-Nucleoside Reverse Transcriptase Inhibitors Market
A. Market Overview
1 Introduction
2 Product Analysis - Existing NNRTIs
3 Product Analysis - Pipeline NNRTIs
4 Market Drivers
5 Market Restraints
B. Market Dynamics
1 Pricing Analysis
2 Revenue Forecasts
3 Market Engineering Analysis
C. Competitive Analysis
1 Competitive Structure
2 Market Share Analysis

6 Future HIV/AIDS Therapies
A. Pipeline ARV Drugs in Novel Categories
1 HIV Entry Inhibitors
2 Immune-Based Therapies
3 Miscellaneous Antiretroviral Therapies
4 Market Share Analysis
B. HIV/AIDS Vaccines
1 Overview
2 Vaccines in Phase III Stage
3 Other Pipeline Vaccines

More United States AIDS, HIV & STDs Reports

The 2012 Herpes Diagnostics Market: US, Europe, JapanTest Volume, Sales Forecasts and Supplier Shares by Country by Venture Planning Group
The report presents a detailed analysis of the Herpes diagnostics market in the US, Europe, (France, Germany, Italy, Spain, UK) and Japan. Current scientific ...

The 2012 HIV/AIDS Diagnostics Market: US, Europe, Japan--Sales Forecasts and Supplier Shares by Country by Venture Planning Group
The report presents a detailed analysis of the AIDS diagnostics market in the US, Europe, (France, Germany, Italy, Spain, UK) and Japan. Current scientific ...

Transfusion Diagnostic Testing Market: US, Europe, Japan--Emerging Opportunities And Business Expansion Strategies for Suppliers by Venture Planning Group
Rationale During the next ten years, the transfusion diagnostics market will undergo significant transformation, which will result from the convergence of several trends, including ...

The 2011 Herpes Diagnostics Market: US, Europe, Japan Test Volume, Sales Forecasts and Supplier Shares by Country by Venture Planning Group
The report presents a detailed analysis of the Herpes diagnostics market in the US, Europe, (France, Germany, Italy, Spain, UK) and Japan. Current scientific ...

The 2011 HIV/AIDS Diagnostics Market: US, Europe, Japan--Sales Forecasts and Supplier Shares by Country by Venture Planning Group
The report presents a detailed analysis of the AIDS diagnostics market in the US, Europe, (France, Germany, Italy, Spain, UK) and Japan. Current scientific ...

See all reports like this >>

More United States Reports

e-Discovery Software Publishing in the US - Industry Market Research Report by IBISWorld
e-Discovery Software Publishing in the US Finding growth : Electronic discovery (more often known as e-discovery) refers to a data search, location and securing process for use ...

D&B Country RiskLine Report: The United States of America by Dun & Bradstreet Inc.
This D&B Country RiskLine Report will help you analyze the risks, opportunities and likely payment delays when doing business in this country. It includes ...

D&B Country Report: The United States of America by Dun & Bradstreet Inc.
D&B Country Report. Comprehensive information for evaluating risks and opportunities when trading or investing in this country. Providing critical information and analysis on ...

Country Report United States January 2011 by Economist Intelligence Unit
Country Reports analyse political and economic trends in featured countries. They show you exactly how national, regional and global events will affect your business in ...

Coal - US - a snapshot (2010) by Mintel - Snapshots
Coal in US by Mintel Global Market Navigator provides you with annual year-end market size data, most recently updated in 2010. This market covers consumption ...

See all reports like this >>

U.S. HIV/AIDS Therapies Markets

Share this report

Other tasks

Research Assistance

Related Markets

AIDS, HIV & STDs Reports

Free Alert Me service